Antiarthritic agents
Investigations into autoimmune diseases have led researchers to uncover a significant association between rheumatoid arthritis (RA) and abnormal glucose metabolism. A recent study published in Experimental and Molecular Pathology found that RA patients with Type 2 Diabetes Mellitus (T2DM) and insulin resistance (IR) have a higher incidence of the disease.
Antiarthritic agents
Scientists at Sun Yat-Sen University have made significant strides in understanding the mechanisms behind rheumatoid arthritis, a chronic autoimmune disease that causes inflammation and pain in the joints. By investigating the role of regulatory T cells (Tregs) in the disease, researchers have identified two key players: CTLA4 and UCP2. These
Apoptosis
Researchers at Shaqra University in Saudi Arabia have made a significant discovery in the field of rheumatoid arthritis (RA) treatment. According to their study, published in the International Journal of Rheumatic Diseases, the team has identified a group of plant-derived compounds that can modulate both inflammation and apoptosis in RA,
Antiarthritic agents
Researchers have found that vagus nerve stimulation can modulate systemic inflammation and may represent a novel non-pharmacologic treatment modality for autoimmune diseases like rheumatoid arthritis. The study, conducted over a 36-month period, involved 14 patients with active RA who had previously failed an average of 4.8 different drugs. The
Antiarthritic agents
Researchers from the University Rovira i Virgili have identified a novel microRNA (hsa-miR) panel that can predict cardiovascular risk in patients with rheumatoid arthritis. The study, conducted over an 8-year period, involved 235 patients with rheumatoid arthritis and found that the hsa-miR panel could accurately predict the progression of atherosclerotic
Antiarthritic agents
New research on rheumatoid arthritis (RA) has shed light on the vital role of regulatory B cells (Bregs) in the immune modulation of the disease. A study conducted by Jinan University Shenzhen People's Hospital found that the levels of CD19+CD24hiCD38hi Bregs in peripheral blood were significantly lower
Adalimumab
Patients with rheumatoid arthritis who are in sustained remission or low disease activity after treatment with tumor necrosis factor inhibitors (TNFi) may be good candidates for treatment de-escalation, according to a new study. Research conducted by a team from Loma Linda University found that discontinuing maintenance TNFi treatment resulted in
Antiarthritic agents
Research on the relationship between rheumatoid arthritis (RA) and metabolic dysfunction-associated steatotic liver disease (MASLD) has revealed a significant association between the two conditions. A population-based study conducted in Austria analyzed data from 6638 participants, including 187 individuals with physician-diagnosed RA. The study found that MASLD prevalence was higher in
Antirheumatic agents
Researchers at Fujian Medical University have conducted a study to assess the association between tofacitinib use and the risk of venous thromboembolism (VTE) events in patients with rheumatoid arthritis (RA). The study, published in Naunyn-Schmiedeberg's Archives of Pharmacology, found that tofacitinib was associated with a significantly elevated risk
Arthritis
A 20-year-old previously healthy man was admitted to a hospital in New Delhi, India, with a two-week history of dull aching pain localized to the anterior chest wall, specifically in the sternum region. The pain was exacerbated by physical activity or deep inspiration. The patient's medical history was
Arthritis
Research published by Riverside Community Hospital estimates that 30.3% of rheumatoid arthritis (RA) patients worldwide have metabolic syndrome (MetS), a condition characterized by central obesity, hypertension, hyperglycemia, and dyslipidemia. The study, which analyzed data from 32 countries, found significant associations between MetS prevalence and clinical variables such as waist
Antirheumatic agents
Researchers at Fujian Medical University have conducted a study to assess the association between tofacitinib use and the risk of venous thromboembolism (VTE) events in patients with rheumatoid arthritis (RA). The study, published in Naunyn-Schmiedeberg's Archives of Pharmacology, found that tofacitinib was associated with a significantly elevated risk
